Type 2 diabetes
Conditions
Interventions
Tofoglifrozin 20mg
Sponsors
Okura Tsuyoshi
Kowa Company, Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes This study will include patients who meet all the following criteria: 2. Age 18-80 years old 3. HbA1c 6.0~10% 4. Diet therapy only, or anti-diabetic medicine, after 12 weeks. Patients who, despite undergoing treatment with diet and exercise therapy, or diet and exercise therapy in addition to other diabetes medications for more than 12 weeks, have not achieved the glycemic control targets set in the Diabetes Treatment Guidelines 2022-2023 and are scheduled to receive tofogliflozin.
Exclusion criteria
Exclusion criteria: 1) Type 1 diabetes 2) Severe ketosis, diabetic coma within the past 24 weeks 3) Severe infection, operation, severe trauma 4) Pregnancy 5) Severe liver dysfunction 6) Severe renal dysfunction 7) Highper sensitivity to SGLT2 inhibitor 8) Urinary tract infection, genital infection 9) Malignancy 10) Administration history of SGLT2 inhibitor within 24 weeks 11) Administration history of insulin injection within 24 weeks 12) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting hepatic insulin clearance after 24 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA-IR after 24 weeks of treatment | — |
Contacts
Public ContactTsuyoshi Okura
Division of Cardiovascular Medicine, Endocrinology and Metabolism, Tottori University Faculty of Medicine
Outcome results
None listed